Gene therapy for neurologic disease: benchtop discoveries to bedside applications. 1. The bench.
暂无分享,去创建一个
[1] A. Lever,et al. Gene therapy for HIV infection , 1998 .
[2] S. Braun,et al. Preclinical studies of lymphocyte gene therapy for mild Hunter syndrome (mucopolysaccharidosis type II). , 1996, Human gene therapy.
[3] W. F. Anderson. End-of-the-year potpourri--1995. , 1995, Human gene therapy.
[4] P. Ryan,et al. Effect of herpes simplex virus thymidine kinase expression levels on ganciclovir-mediated cytotoxicity and the "bystander effect". , 1995, Human gene therapy.
[5] Ronald G. Crystal,et al. Transfer of Genes to Humans: Early Lessons and Obstacles to Success , 1995, Science.
[6] F. Ledley. Nonviral gene therapy: the promise of genes as pharmaceutical products. , 1995, Human gene therapy.
[7] J. Langston,et al. Stereotactic injection of herpes simplex thymidine kinase vector producer cells (PA317-G1Tk1SvNa.7) and intravenous ganciclovir for the treatment of progressive or recurrent primary supratentorial pediatric malignant brain tumors. , 1995, Human gene therapy.
[8] H. Herweijer,et al. A plasmid-based self-amplifying Sindbis virus vector. , 1995, Human gene therapy.
[9] E. Marshall. Gene therapy's growing pains , 1995, Science.
[10] D. Elstein,et al. Recent advances in diagnosis and therapy in Gaucher's disease. , 1995, Israel journal of medical sciences.
[11] R. Schiffmann,et al. Growth factors and stromal support generate very efficient retroviral transduction of peripheral blood CD34+ cells from Gaucher patients. , 1995, Blood.
[12] G. Finocchiaro,et al. The "bystander effect": association of U-87 cell death with ganciclovir-mediated apoptosis of nearby cells and lack of effect in athymic mice. , 1995, Human gene therapy.
[13] I. Dubé,et al. Gene therapy: here to stay. , 1995, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[14] J. Morgan,et al. Myoblast transfer and gene therapy in muscular dystrophies , 1995, Microscopy research and technique.
[15] T. Pugh,et al. In vivo cytokine gene transfer by gene gun reduces tumor growth in mice. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[16] H. DeVroom. The future of neuro-oncology. , 1995, Critical care nursing clinics of North America.
[17] M. Brenner. Human somatic gene therapy: progress and problems , 1995, Journal of internal medicine.
[18] Wheeler Vs. Gene therapy: current strategies and future applications. , 1995 .
[19] L. Soroceanu,et al. Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[20] N. Sarver,et al. Gene therapy and immune restoration for HIV disease , 1995, The Lancet.
[21] S. Meylaerts,et al. Bystander tumoricidal effect in the treatment of experimental brain tumors. , 1994, Neurosurgery.
[22] H. Wakimoto,et al. Adoptive immunotherapy with murine tumor-specific T lymphocytes engineered to secrete interleukin 2. , 1994, Cancer research.
[23] J. Park,et al. Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. , 1994, Cancer research.
[24] K. Hunt,et al. Stereotactic delivery of a recombinant adenovirus into a C6 glioma cell line in a rat brain tumor model. , 1994, Neurosurgery.
[25] L. Doering. Nervous system modification by transplants and gene transfer , 1994, BioEssays : news and reviews in molecular, cellular and developmental biology.
[26] P. Lowenstein. Molecular Neurosurgery: Mending the Broken Brain , 1994, Bio/Technology.
[27] R. Grossman,et al. Adenovirus‐mediated gene therapy of experimental gliomas , 1994, Journal of neuroscience research.
[28] G. Acsadi,et al. The principles of gene therapy in Duchenne muscular dystrophy. , 1994, Clinical and investigative medicine. Medecine clinique et experimentale.
[29] S. Karlsson,et al. Retroviral vector design for long-term expression in murine hematopoietic cells in vivo , 1994 .
[30] N. Wivel. Gene Therapy: Molecular Medicine of the 1990s , 1994, International Journal of Technology Assessment in Health Care.
[31] B. Gansbacher. Cytokine gene therapy. , 1994, The Mount Sinai journal of medicine, New York.
[32] H. Shepard,et al. Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. , 1994, Human gene therapy.
[33] M. Israel,et al. Gene therapy for diseases of the nervous system. , 1994, The Western journal of medicine.
[34] T. Shawker,et al. The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in rats. , 1994, Journal of neurosurgery.
[35] K. Jeang,et al. Gene therapy for human immunodeficiency virus infection: genetic antiviral strategies and targets for intervention. , 1994, Human gene therapy.
[36] W. Anderson,et al. Gene therapy for the treatment of recurrent pediatric malignant astrocytomas with in vivo tumor transduction with the herpes simplex thymidine kinase gene/ganciclovir system. , 1994, Human gene therapy.
[37] F. Gage,et al. Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[38] L. Zitvogel,et al. Retroviral Vectors for Use in Human Gene Therapy for Cancer, Gaucher Disease, and Arthritis a , 1994, Annals of the New York Academy of Sciences.
[39] Z. Ram,et al. In vivo transfer of the human interleukin-2 gene: negative tumoricidal results in experimental brain tumors. , 1994, Journal of neurosurgery.
[40] S. Ponnazhagan,et al. Suppression of human alpha-globin gene expression mediated by the recombinant adeno-associated virus 2-based antisense vectors , 1994, The Journal of experimental medicine.
[41] J. Hauber,et al. Constitutive expression of chimeric neo-Rev response element transcripts suppresses HIV-1 replication in human CD4+ T lymphocytes. , 1994, Human gene therapy.
[42] S. Braun,et al. Metabolic correction and cross-correction of mucopolysaccharidosis type II (Hunter syndrome) by retroviral-mediated gene transfer and expression of human iduronate-2-sulfatase. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[43] D. Wielbo,et al. Antisense inhibition of AT1 receptor mRNA and angiotensinogen mRNA in the brain of spontaneously hypertensive rats reduces hypertension of neurogenic origin , 1993, Regulatory Peptides.
[44] S. Freeman,et al. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. , 1993, Cancer research.
[45] F. Gage,et al. Gene therapy for neurologic disease. , 1993, Archives of neurology.
[46] M. Perricaudet,et al. Long–term correction of mouse dystrophic degeneration by adenovirus–mediated transfer of a minidystrophin gene , 1993, Nature genetics.
[47] Z. Ram,et al. Toxicity studies of retroviral-mediated gene transfer for the treatment of brain tumors. , 1993, Journal of neurosurgery.
[48] S. Rosenberg,et al. Tumor-infiltrating lymphocytes derived from select B-cell lymphomas secrete granulocyte-macrophage colony-stimulating factor and tumor necrosis factor-alpha in response to autologous tumor stimulation. , 1993, Blood.
[49] R. Martuza,et al. An experimental model of retrovirus gene therapy for malignant brain tumors. , 1993, Journal of neurosurgery.
[50] F. Walsh,et al. Direct retroviral-mediated transfer of a dystrophin minigene into mdx mouse muscle in vivo. , 1993, Human molecular genetics.
[51] E. Golanov,et al. Antisense oligodeoxynucleotides to NMDA-R1 receptor channel protect cortical neurons from excitotoxicity and reduce focal ischaemic infarctions , 1993, Nature.
[52] R. Mulligan,et al. The basic science of gene therapy. , 1993, Science.
[53] T. Randall. Gene therapy for brain tumors in trials, correction of inherited disorders a hope. , 1993, JAMA.
[54] W F Anderson,et al. Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. , 1993, Human gene therapy.
[55] B. Sokolov,et al. Use of an antisense oligonucleotide to inhibit expression of a mutated human procollagen gene (COL1A1) in transfected mouse 3T3 cells. , 1993, Biochemistry.
[56] M. Adinolfi. Hunter Syndrome: Cloning of the Gene, Mutations and Carrier Detection , 1993 .
[57] P. Johnson,et al. Dual-target inhibition of HIV-1 in vitro by means of an adeno-associated virus antisense vector. , 1992, Science.
[58] R. Martuza,et al. Gene therapy of maliganant brain tumors: A rat glioma line bearing the herpes simplex virus type 1‐thymidine kinase gene and wild type retrovirus kills other tumor cells , 1992, Journal of neuroscience research.
[59] M. Colombo,et al. Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. , 1992, Cancer research.
[60] L. Huang,et al. Immunotherapy of malignancy by in vivo gene transfer into tumors. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[61] W. McBride,et al. Genetic modification of a murine fibrosarcoma to produce interleukin 7 stimulates host cell infiltration and tumor immunity. , 1992, Cancer research.
[62] S. Karlsson,et al. High levels of human glucocerebrosidase activity in macrophages of long-term reconstituted mice after retroviral infection of hematopoietic stem cells. , 1992, Blood.
[63] Z. Ram,et al. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. , 1992, Science.
[64] K. Davies,et al. Human dystrophin expression corrects the myopathic phenotype in transgenic mdx mice. , 1992, Human molecular genetics.
[65] K. Sikora,et al. Gene therapy for cancer , 1992, The Lancet.
[66] S. Rosenberg,et al. Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[67] M. Atkins,et al. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[68] C Hélène,et al. The anti-gene strategy: control of gene expression by triplex-forming-oligonucleotides. , 1991, Anti-cancer drug design.
[69] G. Acsadi,et al. Conditions affecting direct gene transfer into rodent muscle in vivo. , 1991, BioTechniques.
[70] S. Rosenberg,et al. Immunotherapy and gene therapy of cancer. , 1991, Advances in surgery.
[71] K. Davies,et al. Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs , 1991, Nature.
[72] R. Martuza,et al. Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. , 1991, The New biologist.
[73] D M Coen,et al. Experimental therapy of human glioma by means of a genetically engineered virus mutant , 1991, Science.
[74] A. Asher,et al. Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. Evidence for paracrine immune effects of tumor necrosis factor against tumors. , 1991, Journal of immunology.
[75] H. Volk,et al. Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer , 1991, The Journal of experimental medicine.
[76] R. Fisher,et al. A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[77] S. Rosenberg,et al. Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes , 1991, The Journal of experimental medicine.
[78] W. Anderson,et al. Correction of ADA deficiency in human T lymphocytes using retroviral-mediated gene transfer. , 1991, Transplantation proceedings.
[79] R. Martuza,et al. Gene delivery to glioma cells in rat brain by grafting of a retrovirus packaging cell line , 1990, Journal of neuroscience research.
[80] K. Cornetta,et al. Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. , 1990, The New England journal of medicine.
[81] A. Miller,et al. Progress toward human gene therapy. , 1990, Blood.
[82] F. Moolten,et al. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. , 1990, Journal of the National Cancer Institute.
[83] S. Rosenberg,et al. Unique murine tumor-associated antigens identified by tumor infiltrating lymphocytes. , 1990, Journal of immunology.
[84] S. Fosså,et al. Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study. , 1989, European journal of cancer & clinical oncology.
[85] C. Mettlin,et al. National survey of patterns of care for brain-tumor patients. , 1989, Journal of neurosurgery.
[86] H. Temin. Retrovirus vectors: promise and reality. , 1989, Science.
[87] S. Rosenberg,et al. In vivo distribution of adoptively transferred indium-111-labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma. , 1989, Journal of the National Cancer Institute.
[88] R. Fisher,et al. Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinoma. , 1989, Journal of the National Cancer Institute.
[89] T. Friedmann,et al. Progress toward human gene therapy. , 1989, Science.
[90] R. Stahel,et al. Tolerance and effectiveness of recombinant interleukin-2 (r-met Hu IL-2 [ala-125]) and lymphokine-activated killer cells in patients with metastatic solid tumors. , 1989, European journal of cancer & clinical oncology.
[91] D. Richman,et al. Thymidine kinase obliteration: creation of transgenic mice with controlled immune deficiency. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[92] R. Fisher,et al. A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[93] S M Larson,et al. Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[94] S. Rosenberg,et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. , 1988, The New England journal of medicine.
[95] E. Borrelli,et al. Targeting of an inducible toxic phenotype in animal cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[96] T. Eberlein,et al. Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cells. , 1988, Cancer research.
[97] W. Linehan,et al. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[98] K. Frei,et al. T cell suppressor factor from human glioblastoma cells is a 12.5‐kd protein closely related to transforming growth factor‐beta. , 1987, The EMBO journal.
[99] F. Moolten. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. , 1986, Cancer research.
[100] S. Rosenberg,et al. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. , 1986, Science.
[101] A. Miller,et al. Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production , 1986, Molecular and cellular biology.
[102] A. Chang,et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. , 1985, The New England journal of medicine.
[103] S. Rosenberg,et al. Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells. , 1985, Journal of immunology.
[104] S. Rosenberg,et al. In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. , 1985, Journal of immunology.
[105] S. Rosenberg,et al. Systemic administration of recombinant interleukin 2 stimulates in vivo lymphoid cell proliferation in tissues. , 1985, Journal of immunology.
[106] S. Rosenberg,et al. In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2. , 1985, Journal of immunology.
[107] J. Roth,et al. Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells , 1983, The Journal of experimental medicine.
[108] S. Rosenberg,et al. Lymphokine-activated killer cell phenomenon. Lysis of natural killer- resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes , 1982, The Journal of experimental medicine.
[109] M. Cline,et al. Sounding boards. The potentials of inserting new genetic information. , 1980, The New England journal of medicine.
[110] R. Gallo,et al. Selective in vitro growth of T lymphocytes from normal human bone marrows. , 1976, Science.
[111] J. Lamsam,et al. Gene therapy for solid tumors. , 1995, British medical bulletin.
[112] R. Vile,et al. Retroviruses as vectors. , 1995, British medical bulletin.
[113] H. Klein. Novel cellular therapies. , 1995, Immunological investigations.
[114] J B Martin,et al. Gene therapy and pharmacological treatment of inherited neurological disorders. , 1995, Trends in biotechnology.
[115] A. Minson,et al. Herpes virus-based vectors. , 1995, British medical bulletin.
[116] C. Caskey,et al. Non-viral approaches to gene therapy. , 1995, British medical bulletin.
[117] H. Jinnah,et al. Gene therapy and the brain. , 1995, British medical bulletin.
[118] M. Perricaudet,et al. Adenovirus and adeno-associated virus mediated gene transfer. , 1995, British medical bulletin.
[119] Z. Ram,et al. Adenovirally mediated gene transfer into experimental solid brain tumors and leptomeningeal cancer cells. , 1995, Journal of neurosurgery.
[120] W. Uckert,et al. Retrovirus-mediated gene transfer in cancer therapy. , 1994, Pharmacology & therapeutics.
[121] H. Moser. Gene therapy in neurology. , 1994, European neurology.
[122] C. Mullen,et al. Metabolic suicide genes in gene therapy. , 1994, Pharmacology & therapeutics.
[123] Donald W. Pfaff,et al. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain , 1994, Nature Genetics.
[124] Z. Ram,et al. In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. , 1993, Cancer Research.
[125] C. Caskey,et al. Gene therapy of the immune system. , 1993, Annual review of immunology.
[126] Fulvio Mavilio,et al. Gene therapy , 1993, Nature.
[127] P. Iversen,et al. Cellular uptake and subcellular distribution of phosphorothioate oligonucleotides into cultured cells. , 1992, Antisense research and development.
[128] The ADA human gene therapy clinical protocol. , 1990, Human gene therapy.
[129] R. Blaese,et al. The ADA human gene therapy clinical protocol: Points to Consider response with clinical protocol, July 6, 1990. , 1990, Human gene therapy.
[130] J. Posner. 1 Brain Metastases: A Clinician's View , 1980 .